{"url_path":"/sec/mbrx/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-022087-index.html","accession_number":"0001437749-26-022087","cik":"0001659617","ticker":"MBRX","issuer_name":"Moleculin Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-022087-index.html","primary_entity_key":"0001659617","primary_entity_name":"Moleculin Biotech, Inc."},"word_count":75,"has_tables":true,"body_markdown":"**Item 9.01**\n\n**Financial Statements and Exhibits.**\n\n \n\n(d)\n\nExhibits.\n\n \n\n**Exhibit No.**\n\n**Description**\n\n \n\n99.1\n\n[Investor Presentation dated June 2026](ex_983037_source.htm)\n\n \n\n104\n\nCover page Interactive Data File (formatted as Inline XBRL document)\n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n**MOLECULIN BIOTECH, INC.** \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate:\n\nJune 30, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Jonathan P. Foster\n\n \n\n \n\n \n\nJonathan P. Foster"}